Russia is moving ahead with several prototypes, its officials said, and at least one effort, developed by the Gamaleya Institute in Moscow, has reached advanced stages of testing. The vaccine candidate is similar to one developed by Oxford University and AstraZeneca, using modified viruses that typically cause mild colds in humans.
Russia said it will start so-called Phase III trials of the vaccine this month. In Phase III, trials test for effectiveness in humans, after testing in animals. It is the last stage before approval, allowing widespread use.
The candidate vaccine reportedly has been tested to some extent on soldiers, and the Russian defense ministry said those soldiers all had volunteered. The institute’s director said on Russian television that he himself had also tried the vaccine before it finished testing in monkeys.
Two N.I.H. studies are recruiting patients to test possible Covid-19 treatments.
The National Institutes of Health announced Tuesday the launch of a key second, phase of clinical trials for an antibody treatment to help patients early in the course of Covid-19.
The two studies, which are now recruiting patients, are testing drugs called monoclonal antibodies produced by Eli Lilly and its partner, Abcellera Biologics in Vancouver. Researchers hope to have results in October or November.
The process began in March, and has progressed at “record speed,” said Daniel Skovronsky, chief scientific officer at Eli Lilly. Two and a half months later, the company began safety tests in humans, “surely a record speed,” he said.
The first study, dubbed ACTIV 2, will start with 220 Covid-19 patients who are ill but not hospitalized. Half will receive the antibodies and half a placebo infusion. If there are signs the drug is helping, the trial will expand to a total of 2,000 patients with the hope that the drug reduces the duration of symptoms and speeds the time it takes for the virus to be undetectable in the patients’ upper respiratory tracts.